Adaptive Biotechnologies logo

ADPT - Adaptive Biotechnologies News Story

$34.16 0.4  1.1%

Last Trade - 21/02/20

Sector
Healthcare
Size
Large Cap
Market Cap £3.28bn
Enterprise Value £2.85bn
Revenue £60.2m
Position in Universe 1299th / 6408

BRIEF-Adaptive, Genentech Partner To Use Clonoseq Assay In Study Of Chronic Lymphocytic Leukemia Patients

Mon 13th January, 2020 1:09pm
Jan 13 (Reuters) - Adaptive Biotechnologies Corp  ADPT.O :
    * ADAPTIVE AND GENENTECH PARTNER TO USE CLONOSEQ ASSAY TO
MEASURE
MINIMAL RESIDUAL DISEASE AS A PRIMARY ENDPOINT IN PHASE III
STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
    * ADAPTIVE BIOTECHNOLOGIES - WILL RECEIVE UPFRONT, SAMPLE
TESTING
PAYMENTS TO ADVANCE DEVELOPMENT & POTENTIAL EXPEDITED APPROVAL
OF VENETOCLAX

Source text for Eikon:  ID:nGNX9060m3 
Further company coverage:  ADPT.O 

 ((Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.